Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adamas Pharma (ADMS)

Adamas Pharma (ADMS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 163,805
  • Shares Outstanding, K 27,858
  • Annual Sales, $ 34,050 K
  • Annual Income, $ -131,000 K
  • 60-Month Beta 1.70
  • Price/Sales 3.14
  • Price/Cash Flow N/A
  • Price/Book 8.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.90
  • Number of Estimates 5
  • High Estimate -0.80
  • Low Estimate -1.00
  • Prior Year -1.06
  • Growth Rate Est. (year over year) +15.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.47 +69.45%
on 12/20/19
6.06 -2.97%
on 01/17/20
+1.74 (+42.03%)
since 12/17/19
3-Month
3.47 +69.45%
on 12/20/19
7.45 -21.07%
on 12/16/19
+1.88 (+47.00%)
since 10/17/19
52-Week
3.35 +75.52%
on 10/10/19
12.57 -53.22%
on 03/04/19
-3.05 (-34.15%)
since 01/17/19

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (NASDAQ: ADMS) Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

ADMS : 5.88 (-0.34%)
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.

Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming February 10, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Adamas Pharmaceuticals, Inc. ("Adamas"...

ADMS : 5.88 (-0.34%)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Baozun, Adamas Pharmaceuticals, Cintas, and Correvio Pharma and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Baozun, Inc. (NASDAQ: BZUN), Adamas...

BZUN : 35.56 (-1.47%)
ADMS : 5.88 (-0.34%)
CTAS : 284.23 (-0.80%)
CORV : 0.38 (-1.72%)
ROSEN, A LEADING LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action - ADMS

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) between August 8, 2017 and September 30, 2019, inclusive (the "Class...

ADMS : 5.88 (-0.34%)
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines

Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of ADMS and EXC. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff...

ADMS : 5.88 (-0.34%)
EXC : 47.39 (+1.39%)
DEADLINE ALERT for HEXO, XYF, ADMS, EXC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed...

HEXO : 1.62 (-8.99%)
XYF : 1.77 (+5.31%)
ADMS : 5.88 (-0.34%)
EXC : 47.39 (+1.39%)
Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted two new employees the option to purchase an aggregate of 12,000 shares...

ADMS : 5.88 (-0.34%)
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.

Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming February 10, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Adamas Pharmaceuticals, Inc. ("Adamas"...

ADMS : 5.88 (-0.34%)
INVESTOR ALERT: ADMS and BZUN: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders With Losses Exceeding $100K of Class Action Deadlines

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints...

ADMS : 5.88 (-0.34%)
BZUN : 35.56 (-1.47%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Adamas Pharmaceu (ADMS , FPRX , PBYI , TGTX , BMRN )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

ADMS : 5.88 (-0.34%)
FPRX : 5.31 (+3.11%)
PBYI : 9.73 (+9.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade ADMS with:

Business Summary

Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone...

See More

Key Turning Points

2nd Resistance Point 6.17
1st Resistance Point 6.03
Last Price 5.88
1st Support Level 5.77
2nd Support Level 5.65

See More

52-Week High 12.57
Fibonacci 61.8% 9.05
Fibonacci 50% 7.96
Fibonacci 38.2% 6.87
Last Price 5.88
52-Week Low 3.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar